Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

AACR 2009: Designer T-Cells tackle prostate cancer

AACR 2009

18 - 22 Apr 2009

Published: 30 Apr 2009

Views: 17510

Rating:

Save

Professor Richard Junghans - Associate Professor of Surgery and Medicine, Boston University School of Medicine, USA

Richard Junghans, M.D., Ph.D., associate professor of surgery and medicine, Boston University School of Medicine, presents at AACR 2009, Denver: Phase I Trial of Anti-PSMA Designer T Cells in Prostate Cancer. Cell footage in presentation copyright Cells Alive

Related Videos

Debate: Challenges and solutions for new treatment options in mUC

Dr. María José Juan Fita, Dr. Bernadett Szabados, Prof. Rafael S. Grajewski, Dr...

Debate: Challenges and solutions for new treatment options in mUC ( Dr. María José Juan Fita, Dr. Bernadett Szabados, Prof. Rafael S. Grajewski, Dr. Diego Teyssonneau )

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM

Dr Elias Mai - Heidelberg University, Heidelberg, Germany

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM ( Dr Elias Mai - Heidelberg University, Heidelberg, Germany )

Treating relapsed multiple myeloma outside of use of T-cell redirected therapies

Prof Joy Ho - The University of Sydney, Sydney, Australia

Treating relapsed multiple myeloma outside of use of T-cell redirected therapies ( Prof Joy Ho - The University of Sydney, Sydney, Australia )

Guiding transplant decisions in multiple myeloma with MRD

Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA

Guiding transplant decisions in multiple myeloma with MRD ( Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA )

Revolutionising multiple myeloma treatment with CAR T-Cell therapies

Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA

Revolutionising multiple myeloma treatment with CAR T-Cell therapies ( Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA )

ASCO 2024: Latest in mRCC treatment

Dr Sumanta Kumar Pal, Dr Stephanie Berg, Prof Viktor Grünwald and Prof Thomas...

ASCO 2024: Latest in mRCC treatment ( Dr Sumanta Kumar Pal, Dr Stephanie Berg, Prof Viktor Grünwald and Prof Thomas Powles )

Addition of cabazitaxel to abiraterone/prednisone significantly prolonged PFS...

Dr Christos Kyriakopoulos - University of Wisconsin Carbone Cancer Center...

Addition of cabazitaxel to abiraterone/prednisone significantly prolonged PFS in extensive mCRPC following docetaxel ( Dr Christos Kyriakopoulos - University of Wisconsin Carbone Cancer Center, Madison, USA )

ASCO GU 2024: Latest in PARP inhibitors for prostate cancer

Dr Friederike Schlurmann, Dr Nabil Adra, Dr Emmanuel Antonarakis and Dr Hiroshi...

ASCO GU 2024: Latest in PARP inhibitors for prostate cancer ( Dr Friederike Schlurmann, Dr Nabil Adra, Dr Emmanuel Antonarakis and Dr Hiroshi Kitamura )

OncoAlert round up July 28th to August 3rd, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert round up July 28th to August 3rd, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

More from ecancer